Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €64.31 EUR
Change Today +0.76 / 1.19%
Volume 294.0
As of 9:58 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (4AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/15 - €65.58
52 Week Low
08/6/14 - €37.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBVIE INC (4AB)

abbvie inc (4AB) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

28,000 Employees
Last Reported Date: 07/24/15
Founded in 2012

abbvie inc (4AB) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $923.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $1.5M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $844.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $957.6K
Compensation as of Fiscal Year 2014.

abbvie inc (4AB) Key Developments

European Commission Approves AbbVie's HUMIRA® (Adalimumab) for Moderate to Severe Hidradenitis Suppurativa (HS)

AbbVie announced that HUMIRA® (adalimumab) is approved for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS treatment. HUMIRA is now the first and only medication approved for HS in the European Union. HS, sometimes referred to as "acne inversa" by dermatologists, is a painful, chronic inflammatory skin disease. It is estimated to impact 1% of the adult population worldwide, but prevalence numbers vary across countries. It is characterized by recurrent, painful abscesses and nodules on the skin - typically around the armpits and groin, on the buttocks and under the breasts. HS can have considerable impact on patients' daily lives, their work ability, physical activities and emotional state. HS can be progressive in some people, and surgery may be considered to remove skin affected by the disease in advanced stages. Therefore, diagnosing and managing the disease early is important. This can be difficult, and many people with HS experience a lengthy delay in diagnosis and treatment. It's important for HS patients and people who think they may have HS to see a dermatologist who is trained to recognize and manage the disease.

C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy

C2N Diagnostics and AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). The companies also have begun a Phase 1 clinical study of C2N-8E12 in patients with PSP. C2N-8E12 is a humanized antibody targeting the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer's disease (AD). The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose, multicenter study that will evaluate the safety, tolerability and pharmacokinetics of C2N-8E12 in an estimated 32 subjects with PSP.

Biotest Announces Termination of Tregalizumab Collaboration with AbbVie

Biotest AG and AbbVie Inc. have terminated their collaboration for the development and commercialization of Tregalizumab, which is intended for treatment of rheumatoid arthritis, or RA. AbbVie has exercised its rights to opt-out of the worldwide license, development and commercialisation agreement signed in June 2011. Upon the effective date of termination, AbbVie will return all rights granted under the agreement at no cost to Biotest. Tregalizumab is an investigational humanised anti-CD4 monoclonal antibody, inducing selective activation of regulatory T-cells. As announced on April 24, 2015, the Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with moderate to severe rheumatoid arthritis (RA) did not meet its primary endpoint.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4AB:GR €64.31 EUR +0.76

4AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.50 USD -0.19
Amgen Inc $175.34 USD -1.25
Bristol-Myers Squibb Co $65.64 USD 0.00
Eli Lilly & Co $83.88 USD -0.63
Medtronic PLC $78.06 USD -0.33
View Industry Companies

Industry Analysis


Industry Average

Valuation 4AB Industry Range
Price/Earnings 54.5x
Price/Sales 5.4x
Price/Book 81.0x
Price/Cash Flow 53.5x
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at